Schizophrenia Bulletin Advance Access originally published online on February 15, 2006
Schizophrenia Bulletin 2006 32(2):212-213; doi:10.1093/schbul/sbj061
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.
Editor's Introduction: Theme Issue on Negative Symptoms
2 Department of Psychiatry and Health Behavior, Medical College of Georgia
Keywords: schizophrenia / methodology / clinical trials / drug development
| The first 10% of the full text of this article appears below. |
Although negative symptoms are such an important problem in schizophrenia that no special justification is needed, this theme issue was a response to an initiative by the National Institute of Mental Health (NIMH) to facilitate drug discovery and drug development in the area of negative symptoms. Although there is controversy over the efficacy for negative symptoms of available antipsychotic medications, few would argue that these drugs are satisfactory treatments. NIMH
1To whom correspondence should be addressed; e-mail: bkirkpatrick2@aol.com.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. D. Shepard Editorial--Modeling Negative Symptoms: What's Missing? Schizophr Bull, July 1, 2006; 32(3): 403 - 404. [Full Text] [PDF] |
||||
